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Abstract
The ongoing epidemics of opioid overdose raises an urgent need for effective anti-addiction 
therapies and addiction-free painkillers. The κ–opioid receptor (KOR) has emerged as a promising 
target for both indications, raising demand for new chemotypes of KOR antagonists, as well as G-
protein-biased agonists. We employed the crystal structure of the KOR-JDTic complex and ligand-
optimized structural templates to perform virtual screening of available compound libraries for 
new KOR ligands. The prospective virtual screening campaign yielded a high 32% hit rate, 
identifying novel fragment-like and lead-like chemotypes of KOR ligands. A round of 
optimization resulted in eleven new sub-micromolar KOR binders (best Ki = 90 nM). Functional 
assessment confirmed at least two compounds as potent KOR antagonists, while compound 81 was 
identified as a potent Gi biased agonist for KOR with minimal β-arrestin recruitment. These results 
support virtual screening as an effective tool for discovery of new lead chemotypes with 
therapeutically relevant functional profiles.
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INTRODUCTION
The classical μ, δ, and κ opioid receptors are G protein-coupled receptors (GPCRs) that play 
critical roles in pain, addiction and mood disorders.1–3 As such, opioid receptors are the 
targets for widely prescribed pain medications that often carry a major drug abuse 
liability.4, 5 Among the three opioid receptors, the κ-opioid receptor (KOR), is widely 
expressed throughout the central and peripheral nervous systems and is activated by the 
endogenous peptide dynorphin. KOR has a special physiological profile, associated with 
pain relief on one hand, and stress exacerbation and mood suppression on the other.6, 7 
Moreover, there is accumulating evidence that dynorphin may serve as a body’s natural 
addiction control mechanism.6, 8 Exogenous KOR agonists, like the plant derived salvinorin 
A9 and the synthetic compound U-25048810 (Chart 1) are known to be effective in pain 
relief, but can also induce hallucinations and dysphoria,11 and therefore are deemed 
unsuitable as CNS analgesics. At the same time, KOR antagonists, such as NorBNI and 
JDTic have been in active development as potential antidepressants, anxiolytics and anti-
addiction drugs.12, 13 In particular, JDTic showed robust response in rodent models of 
depression, anxiety, stress-induced cocaine relapse, and nicotine withdrawal.14–17 Although 
clinical development of JDTic was abandoned due to transient cardiovascular effects18 and 
exceptionally long lasting action,19 several other KOR selective antagonists are in various 
stages of clinical or preclinical studies.20, 21
In addition, it was recently shown that the KOR induced dysphoric and sedative effects are 
mediated by arrestin recruitment to KOR and corresponding signaling via p38 MAPK 
pathway activation.11, 22 Therefore, biased KOR agonists that activate the Gi/o pathway, but 
have reduced β-arrestin mediated responses, can possess the desired pain relief effects 
without the unwanted side effects. Indeed, several G-protein biased ligands, including 6′-
guanidinonaltrindole (6′-GNTI),23 and the Salvinorin A derivative RB64,22 (Chart 1) have 
shown analgesia with significantly reduced addiction risk in animals, and several new series 
of biased KOR agonists are being actively developed.24, 25 However, the KOR ligand 
chemotypes are still largely limited to morphinans, diterpenes and JDTic analogues, so 
expanding their repertoire for both KOR antagonists and biased agonists would be highly 
beneficial for drug discovery.
A unique opportunity to effectively screen for new KOR ligand chemotypes is presented by 
the recently solved crystal structures of opioid receptors, including the high resolution 
structures of the KOR-JDTic complex26 (PDB ID 4DJH), morphinan bound δ-opioid 
receptor27 (DOR, PDB ID 4N6H) and μ-opioid receptor28 (MOR, PDB ID 4DLK). 
Structure-based virtual ligand screening (VLS) campaigns have been previously successful 
in discovery of novel ligand chemotypes for many GPCRs activated by small-molecule 
ligands, including new antagonists for β2 adrenergic,29 A2A adenosine,30, 31 H1 histamine,32 
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D3 dopamine,33 as well as agonists for β2 adrenergic,34 allosteric modulators for D3 
dopamine,35 and more. Although opioid and other peptide- and protein-binding GPCRs 
present special challenges for virtual screening, usually limiting affinity of initial hits to the 
micromolar range,36–38 such screening has already demonstrated great utility, e.g. in 
discovery of a new class of MOR Gi-biased agonists with analgesic activity and reduced side 
effects.39
In this study we employed a multi-template screening strategy using the crystal structure of 
KOR and corresponding ligand-optimized atomistic models40 to discover several new KOR 
chemotypes with sub-micromolar activities and distinct functional features. The initial 
prospective screening achieved a 32% hit rate and identified six new promising lead-like 
scaffolds, while the follow up round of structure-activity relationship (SAR) yielded eleven 
additional hits in sub-micromolar affinity range. Functional characterization shows KOR 
antagonist or agonist activity for a number of new ligands, while compound 81 was 
identified as an agonist with a G-protein biased profile, relevant for therapeutic applications.
RESULTS
Benchmark docking and optimization of receptor models
To evaluate the performance of the structural models in correctly separating KOR binding 
compounds from inactives, we first performed a benchmark VLS using known KOR ligands 
and a decoy compound library (Figure 1). Docking into the model directly derived from the 
KOR-JDTic crystal structure (Model 1) showed high binding scores and conformations of 
JDTic analogues that were consistent with the crystal structure (PDB ID 4DJH).26 Docking 
poses for most morphinans in Model 1 were also consistent with the morphine core 
conformations found in crystal structures of other opioid receptors,27, 41 forming an anchor 
salt bridge between protonated amine and the carboxyl of Asp138. However, the docking 
scores calculated for KOR morphinan ligands and other non-JDTic chemotypes were 
suboptimal, resulting in the overall poor VLS benchmark performance of Model 1 (Figure 
1c). This comes as no surprise, because the JDTic-bound conformation of the KOR 
orthosteric pocket (PDB ID 4DJH)26 is quite distinct from the pocket conformation in 
morphinan-bound opioid receptors, e.g. DOR (PDB ID 4N6H)27 or MOR (PDB ID 
4DKL),28 despite almost exact residue conservation in the interaction sites.42 Thus, JDTic 
binds deeper in the pocket than the morphine scaffold, breaking a hydrogen bond interaction 
between Asp138 and Tyr320, which is otherwise conserved in opioid receptor structures, as 
well as in majority of aminergic receptors.43 This distinct JDTic-bound conformation in the 
KOR structure is apparently suboptimal for binding of morphinans and some other 
chemotypes, and requires separate treatment.
To develop a more accurate model for docking of non-JDTic chemotypes, we employed 
ligand-guided optimization of the binding site using morphinans as seed compounds. The 
first optimization approach used the same JDTic bound crystal structure of KOR as a starting 
point (4DJH),26 and performed extensive refinement of the pocket conformation in presence 
of morphinans. The second approach used a model of KOR, built by homology from the 
DOR crystal structure template (PDB code 4N6H)27 as a starting point for ligand-guided 
optimization. The best performing models from these two approaches, referred to as Model 
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2 and Model 3, had better binding scores for morphinan ligands, which is reflected in their 
improved overall performance in the VLS benchmark (Figure 1c). The optimized Models 2 
and 3 were selected for use in prospective VLS alongside with the original KOR crystal 
structure (Model 1).
Prospective VLS and identification of novel KOR binders
A commercial library of 4.5 million compounds was docked into all three different receptor 
models as described in Methods, and the binding scores were predicted for the best docking 
conformations. For each VLS run, the top 1000 compounds with the highest docking score 
were selected, and clustered based on their chemical structures. The Tanimoto distances 
were calculated for these compounds to evaluate their similarity with known KOR ligands, 
and the close analogues were removed. A final group of compounds was selected for 
purchase based on their chemical diversity, structural novelty and predicted binding affinity 
(Chart S1). Following mass spectrometry quality and purity verification, 43 compounds (18, 
20 and 5 compounds for Models 1, 2 and 3, respectively) were tested for activity.
The candidate hits predicted by the virtual screen were tested for inhibition of 6H-U69593 
binding to cloned human KOR at 50 μM concentration (Table S1). The compounds that 
showed at least 30% inhibition were further tested in concentration-response binding assays 
to determine KOR binding affinities; binding curves of six of the most potent compounds are 
shown in Figure 2. The best compounds identified by the virtual screen are listed in Table 1 
and Chart 2. Out of the 43 tested compounds, binding affinity better than Ki <10 μM was 
measured for 14 compounds, which amounts to a 32% overall hit rate. Five of the hit 
compounds came from the KOR crystal structure-based Model 1 (27% hit rate), seven come 
from the ligand-optimized Model 2 (35% hit rate), and two from homology-based Model 3 
(40% hit rate). The two most potent compounds discovered in the initial VLS round (28 and 
11) had binding affinities of 0.2 and 0.5 μM, respectively.
The ligand efficiencies (LE) were found in the lead-like range for the vast majority of the hit 
compounds.44 Four of the hit compounds (16, 3, 40 and 29) had molecular weight less than 
300 Da and satisfied the “rule of three” as fragment-like compounds. A fragment-sized 
compound 29 with a molecular weight of 163 Da reached the best LE = 0.59 kcal/mol per 
heavy atom. Overall, 11 hits had LE better than 0.3 kcal/mol per heavy atom. The small 
molecular weight and high LE can provide ample room for the further optimization of these 
fragment-like and lead-like hits.
All the discovered ligand chemotypes are novel to KOR, with 10 out of 14 compounds 
showing a Tanimoto distance > 0.3 to the known KOR ligands. The fragment-like compound 
29 had the lowest Tanimoto distance (0.15), as its tetrahydronaphthalene ring structure has 
similar (but still distinct) chemotype as the tetrahydroisoquinoline core substructure of 
JDTic. Identification of this fragment by VLS confirms the established role of JDTic-like 
scaffolds as KOR drug-discovery leads.
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Chemical and conformational diversity of the hit compounds
The newly identified ligands by VLS encompass a diverse set of chemical scaffolds, the top 
six of which are exemplified by compounds in Chart 2. The first scaffold, represented by 
compound 28 contains an imidazole ring and a phenol group. The second scaffold, 
represented by compound 11 has a phenol-ethyl-piperidine motif. The other two top 
chemotypes, represented by compounds 21 and 40 contain fused rings, benzofuran and 
benzooxazol, respectively. Compound 43 has a urea core, while compound 6 is based on 
amino-phenyl-ethanol scaffold, which can be found in some β2-adrenergic agonists, both not 
in previously documented KOR ligands.
Figure 3 shows the predicted binding for the six top chemotypes in their corresponding 
models of KOR. It illustrates the common salt bridge interactions between amino groups of 
the ligands and the carboxyl group of Asp138, but also the variety of secondary interactions. 
Thus, compounds 28, 11 and 6 are predicted to place a hydroxyphenyl group in the 
hydrophibic pocket flanked by transmembrane helices III, V, and VI, where it also forms a 
hydrogen bond to a conserved water molecule similar to water-mediated interactions of 
known ligands in opioid receptor structures. The same conserved subpocket in all opioid 
receptors is known to accommodate the phenoxy ring of the N-terminal Tyrosine residue of 
endogenous peptides, as well as in morphinans.27, 28 This interaction involves hydrophobic 
contact with Met142 and Ile294 side chains, but also a hydrogen bond network mediated by 
a highly conserved water molecule (Figure 3 a,b,f). Another three compounds, 21, 43 and 40 
were predicted to extend more towards helix I and/or the extracellular side of the pocket, 
expanding the repertoire of contacts employed by the KOR ligands. Although the sidechain 
of Asp138 was given full flexibility in the docking models, the conformational changes in 
this sidechain are minor, and the residue retains a similar rotamer in most ligand complexes.
Initial optimization of the hit scaffolds
In the first round of compound optimization, we proceeded to explore the analogues of the 
top six chemical scaffolds identified by structure-based VLS, and assess their binding and 
functional properties. The search was performed for the top compounds based on chemical 
fingerprint similarity, followed by docking of the analogues into the structural models of 
KOR. Ten analogues each were selected for 28 and 11 chemotypes, and five analogues each 
were selected for 21, 43, 40 and 6 chemotypes (Chart S2), allowing us to explore available 
derivatives and to establish initial SAR for lead optimization.
These 40 analogue compounds were acquired from chemical vendors and tested in KOR 
binding assays. All 40 compounds displayed at least 30% inhibition at 50μM concentration, 
and therefore all were tested in the concentration-response binding assay to obtain binding 
affinities (Table S2). As many as 33 out of the 40 tested compounds showed Ki values of 10 
μM or lower, and 11 compounds had sub-micromolar affinities up to Ki = 0.09 μM (Figure 
4, Table 2 and Chart 3). The ligand efficiencies had also improved, with all 11 top hits 
having LE > 0.32 kcal/mol per heavy atom and six of them with LE> 0.4 kcal/mol per heavy 
atom. Compound 81, which is the second most potent ligand identified, had the best LE > 
0.53 kcal/mol per heavy atom. All 11 of the most potent compounds represent scaffolds 28, 
11, 21 and 6 (Chart 3). In particular, all five compounds from scaffold 21 display very good 
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binding affinities with a Ki < 1μM. Scaffold 6 looks promising as well, as it yielded the first 
and the third best affinity compounds in the whole set. Three of the compounds in scaffold 
28, were identified as potent binders, including 81. These results suggest selection of leads 
for further optimization, with scaffolds based on compounds 28, 21 and 6 looking the most 
encouraging.
Effect of mutations on ligand binding
The affinities of the seven most potent KOR ligands identified in this study were retested in 
wild type (WT) KOR and 6 single point mutants (Table S3). Expression levels and 6H-
U69593 radioligand binding were comparable with those of WT in most cases, except for 
mutants D138A and D138N, which had greatly reduced binding affinity for 6H-U69593 and 
were excluded from further assessment. The affinity of Sal A in WT KOR and mutants were 
found comparable with previously reported values.42 The results in Table S3 show distinct 
effect of mutations on binding different ligands. Thus, M142A mutant reduced binding of 
64, 67 and Sal A at least 10 fold, at the same time enhancing binding of 69, 70 and 72. 
Mutations H291A and I294A resulted in more than 10 fold reduction of 64, 67, 81 and 87 
affinity, while not affecting binding of the other three newly identified compounds or 
salvinorin A. This is in agreement with the predicted binding poses of the compounds 
(Figure 5), where the hydroxy phenyl moiety of compounds 64, 67, 81 and 87 are stacked 
between the hydrophobic side chains of Met142 and Ile294, while the hydroxy group can 
form hydrogen bonds via bridging waters to His291. In case of compounds 69 and 72, their 
hydrophobic benzofuran moieties do not reach His291 and Ile294 in helix VI, and also lack 
suitable polar groups capable of forming hydrogen bonds in this subpocket. Interestingly, for 
both 69 and 72, an increase in ligand binding was observed for M142A mutations, reflecting 
plausible steric strain between their large subsituted benzofuran group and Met142.
Functional characterization of the novel KOR ligands
The top 11 sub-micromolar compounds from the analog optimization set and the top 6 
original VLS hits were further characterized in Gi-cAMP and β-arrestin recruitment (Tango) 
assays to probe their functional profiles at KOR (Figures 6 and 7). Most of the new KOR 
ligands exhibited pronounced antagonist activity in Tango assays (Figure 6a), with the ligand 
64 completely inhibiting Sal A-induced β-arrestin recruitment. In the agonist mode of the 
Tango assays, only compound 28 showed measurable β-arrestin recruitment activity at 10 
μM (Figure 6b and 7a). In contrast, in the Gi-mediated inhibition of cAMP production 
assays, a number of compounds showed agonism at 10 μM, with compounds 28 and 81 
inducing as much activity as Sal A (95% and 80% of Sal A activity, respectively) (Figure 
6c). Several other compounds (40, 69, 72, 70) showed partial (40%–60%) activation of the 
receptor in the cAMP assays.
The highest affinity compounds 64 and 81 were then further tested for their antagonist and 
agonist activity in a concentration-dependent manner. In the β-arrestin recruitment assays 
(Figure 7b), compound 64 inhibited Sal A activity with an IC50 value of 1.1 μM (pIC50 = 
5.96 ± 0.33). According to Cheng-Prusoff equation,45 the estimated functional affinity of 64 
was 0.23 μM (pKi = 6.63 ± 0.20), while in the Gi-mediated inhibition of cAMP production 
assays, Schild analysis indicated KB = 0.17 μM (Figure 7c). The values from these two 
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functional assays were comparable with each other and with the compound 64 binding 
affinity (Ki = 0.09 μM), suggesting consistent antagonism of 64 in the sub-micromolar 
range.
Most interesting though, agonist 81 showed much stronger agonist activity in the Gi-
pathway (EC50 = 0.53 μM) than in the arrestin pathway (EC50 = 8.1 μM) and analysis of the 
pooled results46 indicated that compound 81 has a Gi-bias factor of 6.0 over arrestin 
recruitment (Figure 7d). Compounds 28 and 81, the two with the strongest KOR agonist 
activity, were also tested at DOR and MOR for Gi-mediated inhibition of cAMP production. 
Results show at least 50% and 70% reduced agonist activity at either DOR or MOR (Figure 
S1), suggesting KOR selectivity of these compounds.
DISCUSSION
Development of novel antagonists and G-protein biased agonists for KOR is a highly 
promising strategy for effective and potentially liability-free treatment of pain, anxiety and 
addictive disorders.20, 21 This study employed crystal structure-derived models of KOR26 
and a multi-template VLS approach to discover new fragment-like and lead-like chemotypes 
for KOR. The initial round of structure-based prospective VLS resulted in a high hit rate 
(32%) and the discovery of at least six novel KOR chemotypes, with best ligand affinity Ki = 
0.2 μM. High prospective hit rate, diversity and potency of the best hits in this study are on 
par with most successful structure-based VLS campaigns for small-ligand-binding GPCRs 
including adrenergic β2-adrenergic,29 adenosine A2A,30, 31 histamine H1,32 and dopamine 
D3,35,33 receptors. This outcome is very encouraging for KOR, because its large orthosteric 
site is optimal for binding of endogenous peptides, but represents a substantial challenge for 
structure-based discovery of small molecule ligands.36, 37
Our initial benchmarking of the structural VLS models and prospective screening results 
suggest several key strategies helping to improve VLS performance and discover chemically 
and functionally diverse high affinity chemotypes. One of them is inclusion of relevant 
tightly bound water molecules in the screening models. Thus, the initial benchmarks of the 
KOR structure-based models with a set of known ligands suggested poor performance of the 
structural models that have all water molecules removed. Inclusion of the tightly bound 
waters, conserved between high-resolution opioid receptor structures yielded Model 1. This 
model improved docking poses and scores for JDTic and similar compounds, due to 
formation of the water mediated interactions with the receptor. Water interactions play 
important role in ligand binding, and accounting for water molecules is essential in ligand 
docking for many GPCRs,47 including opioid receptors.26,48, 49 Therefore, we believe that 
the current trend for explicit inclusion of relevant waters in VLS models30, 50, 51 is an 
important step for improved virtual screening efficiency in GPCRs.
Another major factor for effective VLS in this study is ligand-guided optimization strategy 
to generate multiple screening models for KOR.40, 52 Thus, our assessment showed that even 
though water inclusion in Model 1 improved binding of JDTic-like compounds, the model 
was still suboptimal in VLS benchmarks of other compounds, such as morphinans. Ligand-
guided optimization with morphinan 6′-GNTI as a seed compound led to Models 2 and 3 
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with dramatically improved performance for morphinan-based compounds and overall 
(Figure 1). While Model 2 was limited to side-chain optimization of the KOR pocket, Model 
3 was generated using homology modeling, starting with the high-resolution crystal 
structure of morphinan-bound DOR.27 The rationale for using a homology model is very 
high sequence and structural conservation between the core binding pockets of the two 
opioid receptors, and a hypothesis that morphinan scaffolds make similar interactions in the 
two receptors, shaping the pocket conformations in the two receptors similarly. All three 
models were employed in perspective VLS using the multiple template approach,53 which 
resulted in a 26% hit rate for Model 1, and even higher 35% and 40% hit rates for optimized 
Models 2 and 3 respectively. Though the number of compounds tested for each model is not 
sufficient to establish statistical significance of improved hit rates for Models 2 and 3, this 
result suggests that ligand-optimized VLS models, including homology-based, can be 
beneficial for overall performance of screening and yield more chemically and functionally 
diverse chemotypes.
We also noted that reproducibility of the KOR docking models critically depends on 
extended ligand sampling in docking procedure, requiring at least 5 times more sampling as 
compared to GPCRs with small molecule cognate ligands. As mentioned above, the large 
size and relatively open shape of the KOR binding pocket is more suitable for peptide 
interactions than for small molecule binding. It creates a substantial challenge that should be 
taken into account in VLS attempts not only for opioid receptors, but for other peptide and 
protein-binding receptors.
Based on experimental validation, the high ligand efficiency (LE) for many of the discovered 
compounds (LE > 0.40 kcal/mol per heavy atom) suggests the potential utility of these KOR 
ligands as leads for optimization. Indeed, the analogue search performed for the best six 
chemotypes resulted in identification of 33 additional hits with Ki < 10 μM, of which 11 had 
sub-micromolar affinities in the binding assays. Scaffolds 28, 21 and 6 have multiple sub-
micromolar analogues and, therefore, present promising candidates for further optimization 
for their affinity, selectivity and functional properties.
Functional assessments performed for the new sub-micromolar ligands shows KOR 
antagonism for most of these compounds in both β-arrestin recruitment (Tango assay) and 
G-protein activation (Gi-cAMP assay). The most potent antagonist identified is compound 
64 (Scaffold 6), which has the highest affinity (Ki = 0.09 μM), and comparable potencies Ki 
= 0.23 μM and KB = 0.17 μM in β-arrestin and G-protein assays respectively (Figure 7b,c), 
suggesting that 64 is a balanced antagonist. The two most potent agonists discovered here 
belong to the same chemotype (scaffold 28) and have similar affinities (Ki = 0.16 μM). 
However, while 28 has balanced activity in both arrestin and G-protein assays, compound 81 
apparently shows characteristics of G-protein biased agonist with G-protein KB= 0.17 μM, 
and Gi-bias factor of 6.0 over arrestin recruitment (Figure 7d). Interestingly, compound 81 
represents a substructure of 28, after removal of the methyl moiety from its amino group and 
3-fluoromethyl from diazole ring. The first modifications can increase flexibility of the 
ligands at the amine located in the middle of the compound and anchored at Asp138 side 
chain conserved in opioid receptors. The other modification removes the 3-fluoromethyl 
group that points towards conserved Trp287 side chain, which is implicated in activation 
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mechanism in opioid receptors.54 Both changes can easily impact the activation profile, and 
lead to biased signaling of 81, though further SAR analysis will be required to fully 
understand the mechanisms involved in biased signaling of KOR.
CONCLUSIONS
Prospective VLS for novel chemotypes of KOR ligands shows high hit rate for fragment-like 
and hit like compound libraries (32%), combined with high ligand affinities (Ki= 0.09 μM) 
and ligand efficiencies (LE > 0.40 kcal/mol per heavy atom) for the best hit compounds 
suggesting their amenability for optimization. The initial round of optimization resulted in 
11 sub-micromolar hits based on four distinct novel chemotypes, providing further insights 
for lead optimization of these scaffolds. Functional characterization reveals a number of 
antagonists with the best KB = 0.17 μM, and a few agonists, most potent of which, 81, has a 
strong preference to G-protein pathway (bias factor 6.0, calculated with Sal A as a reference 
compound as described in ref.46), which has been associated lower addiction liability and 
fewer side effectsfor KOR-targeted analgesics.22
EXPERIMENTAL SECTION
Binding assays
Radioligand binding assays with 6H-U69593 were performed using cloned, human KOR 
receptors expressed in HEK293 cells as previously detailed in ref.55 and PDSP assay 
protocols (https://pdspdb.unc.edu/pdspWeb/?site=assays). Initial primary screening assays 
were carried out at the single concentration of 50 μM in quadruplicate. Compounds with a 
minimum of 30% inhibition were subjected to concentration-response binding assays (12 
points ranging from 100 μM to 10 nM in triplicate) to determine their binding affinities, Ki. 
Quality and purity of all tested compounds was verified using mass spectrometry; 5 out of 
48 initially obtained compounds (1, 14, 23, 32, 47) were excluded from further consideration 
due to inadequate quality. With the exception of compounds 6, 20 and 30, which had >90% 
purity, all the remaining compounds were certified at >95% purity (Table S1).
Ligand efficiency (LE) was calculated for the hits as the ratio of experimental affinity and 
number of heavy atoms in the molecule: LE = 1.4(−logKi)/N (ref44, 56). High value of LE 
(usually > 0.3 kcal/mol per heavy atom) is considered one of the key properties of a 
compound that reflects its propensity for successful lead optimization.
KOR-arrestin translocation assays
KOR Tango assays were performed as described.57 Briefly, HTLA cells were transfected 
overnight and then plated in DMEM supplemented with 1% dialyzed FBS in Poly-L-Lys 
(PLL) coated 384-well white clear bottom cell culture plates at a density of 15,000 cells per 
well in total of 40 μl. The cells were incubated for at least 6 h before receiving drug 
stimulation. Drug solutions were prepared in DMEM with 1% dFBS at 5× and added to cells 
(10 μl per well) for overnight incubation. For antagonist assays, 30 nM of reference agonist 
(Sal A) was added 30 min after compounds. The next day, media and drug solutions were 
removed and 20 μl per well of BrightGlo reagents (purchased from Promega, after 1:20 
dilution) were added. The plate was incubated for 20 min at room temperature in the dark 
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before being counted using a luminescence counter. Results (relative luminescence units) 
were plotted and analyzed in GraphPad Prism 5.0.
cAMP assays
HEK293T cells were co-transfected with human KOR receptor along with a split luciferase-
based cAMP biosensor (GloSensor; Promega) as described57 with modifications. In brief, 
transfected cells were plated in Poly-L-Lys coated 384-well white clear bottom cell culture 
plates with DMEM + 1% dialyzed FBS at a density of 15,000 cells per 40 μl per well 
overnight. On the day of assay, cells were removed of culture medium and loaded with 20 
μl/well assay buffer (20 mM HEPES, 1× HBSS, pH 7.4) supplemented with 4 mM luciferin 
for 1 hour. To measure agonist activity for Gi coupled receptors, we added 10 μl of 3× of 
drug solutions for 15 min, followed by 10 μl of Isoproterenol at a final concentration of 200 
nM (to activate Gs via endogenous β2-adrenergic receptors), and luminescence intensity was 
quantified 15 min later. To measure antagonist activity at Gi coupled receptors, cells were 
preincubated with drugs for 15 min before the addition of 20 nM reference agonist (Sal A) 
for another 15 min, then 10 μl of isoproterenol at final concentration of 200 nM was added 
and luminescence was quantified 15 min later. Results (relative luminescence units) were 
plotted and analyzed in GraphPad Prism 5.0. Transduction coefficients log(τ/KA) and ligand 
bias ΔΔlog(τ/KA) were calculated as described by Kenakin et al.46
Mass spectrometry analysis
LCMS data for all compounds were acquired using an Agilent 6110 series system with a UV 
detector set to 220 nm. To each well of a Greiner 96 well plate with 2 μL of each sample (10 
mM solution in DMSO) we added 38 μL of MeOH. After mixing, 15 μL of each sample was 
injected onto an Agilent Eclipse Plus 4.6 × 50 mm, 1.8 μm, C18 column at room 
temperature (rt) at a flow rate of 1.0 mL/min. A linear gradient from 10% to 100% (vol/vol) 
B over 5.0 min followed by 2.0 min at 100% B with a mobile phase of (A) H2O + 0.1% 
acetic acid and (B) MeOH + 0.1% acetic acid was used. Mass spectra (MS) data were 
acquired in positive ion mode using an Agilent 6110 series single quadrupole mass 
spectrometer with an electrospray ionization (ESI) source.
Generation of Receptor Models
The virtual screening models of KOR were prepared from three different sources. The first 
model (Model 1) was built using the KOR crystal structure (PDB ID: 4DJH) with the 
molecular object conversion procedure implemented in ICM molecular modeling software 
(www.molsoft.com). The procedure includes the addition of hydrogen atoms, selection of 
the energetically favorable conformations of His, Asn, and Gln side chains, and local 
minimization of polar hydrogens using the internal coordinates space. Five water molecules 
in the orthosteric binding site, preserved in high resolution structures of opioid receptors 
were retained in the model. Hydrogen atoms of the structured water molecules were co-
optimized together with KOR hydrogens, while coordinates of water oxygen atoms were 
retained as in the crystal structure. The second receptor model (Model 2) was generated 
starting with the same KOR crystal structure (PDB ID: 4DJH) by co-optimizing it with the 
morphine derivative 6′-GNTI. The compound 6′-GNTI was initially placed into the binding 
site by superimposing it with the naltrindole as in DOR complex structure27 (DOR, PDB ID 
Zheng et al. Page 10
J Med Chem. Author manuscript; available in PMC 2017 June 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4N6H). The resulting KOR-6′-GNTI complex was optimized using energy-based global 
optimization with ICM Biased probability Monte Carlo procedure,58 where full flexible 
sidechains of residues within 5 Å of the ligand were extensively sampled to accommodate 
the compound.
The third receptor model (Model 3) was built using KOR homology model generated from 
the high resolution structure of DOR (PDB ID: 4N6H)27, which shares as much as 70% 
sequence identity to KOR. The homology modeling procedure in the ICM Model Builder58 
inherits the conformation of the template backbone in the conserved residues regions, while 
re-optimizing conformation of the non-conserved sidechains and loop regions. Finally, the 
global energy optimization procedure was then performed for the KOR-6′-GNTI complex as 
describe for Model 2 above.
To validate the ICM VLS models, a small set of 100 known KOR ligands from the ChEMBL 
database59 were mixed with a decoy set of 900 compounds, and docked into all three 
receptor models. The docking models were analyzed for their ability to separate ligands 
from decoys by calculating its Receiver Operator Characteristic (ROC) curves, which were 
plotted with True Positive Rate on the Y axis vs False Positive Rate on the X axis. Based on 
the calculated area under the ROC curve (AUC) and normalized square root AUC 
(NSQ_AUC) (ref.40) the ligand-optimized Models 2 and 3 show improved VLS benchmark 
performance as compared to the original Model 1.
Virtual Ligand Libraries
Lead-like and fragment-like libraries were built using commercial compounds from five 
vendors (Chembridge, Enamine, Life Chemicals, Chemdiv and Maybridge). The libraries 
contain 4.5 million compounds in total. Duplicates and compounds with molecular weight 
more than 500 Da were removed. Compounds were also filtered to exclude reactive 
functional groups and promiscuous PAINS chemotypes.60 Compound formal charges were 
assigned at pH 7 using the pKa calculation module within ICM software.58
The Tanimoto chemical similarity distances between the VLS hits and known ligands of 
KOR were calculated using dynamic linear fingerprints in the ICM-pro suite.58 Compounds 
with a Tanimoto distance of less than 0.3 Å are considered similar in a chemical search. The 
search was performed in the ChEMBL database59 subset of ligands with affinity higher than 
10 μM to any of the KOR orthologues.
Virtual Screen
Virtual screens of the 4.5 million compounds library for each model were carried out using 
the ICM VLS procedure with partial flexibility in the binding pocket.58 The receptor all-
atom models were transformed into energy potential maps calculated using a fine 3D grid 
(0.5 Å). Energy terms including van der Waals, hydrogen-bonding, hydrophobic, and 
electrostatic interactions between the ligand and the receptor were taken into account. The 
anchor binding sidechain of Asp138 was excluded from this grid potentials, and its 
conformation and interactions with ligand were treated explicitly as in an all-atom model 
with flexible torsion angles. In virtual screen docking, ligands were given full torsion 
flexibility in internal coordinates. The docking was performed using a Monte Carlo global 
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energy minimization procedure. The conformation of each compound was sampled using 
BPMC algorithm61 and scored to find the best binding energy. The initial benchmark virtual 
screens with the default thoroughness level 1 yielded only ~25% redundancy among the top 
ranked compounds predicted in two independent runs. The same test performed using 
thoroughness level of 5, however, achieved ~60% overlap between independent screening 
results. This benchmark suggests that the large size of the KOR binding pocket may require 
a higher thoroughness level of sampling to achieve robust docking convergence. The final 
virtual screen for the full compound library was performed with a thoroughness level of 5 to 
enhance convergence. No empirical constraints on ligand conformation were used in the 
docking. Overall, each virtual screen run on the 4.5 million compound library used 28,000 
CPU core hours on Linux workstations totaling 128 CPUs cores.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Optimization and validation of the models with known KOR ligands
Docking poses of morpine (a) and nalfurafine (b) in the binding pocket of the optimized 
Model 3. Ligands are shown as sticks with carbon atoms colored magenta. Receptor is 
shown by grey cartoon and sticks, and tightly bound water molecules directly involved in 
ligand binding as red spheres. (c) ROC curves calculated for the KOR crystal structure 
(Model 1) and the two ligand-optimized models (Model 2 and Model 3).
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Figure 2. Radioligand competition binding assays for the compounds predicted by structure 
based VLS
Concentration response curves for the top 6 hit compounds with KOR binding affinity (Ki) 
better that 3 μM. Normalized results (mean ± SEM) from three independent assays (each in 
triplicate) were pooled and analyzed in GraphPad Prism.
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Figure 3. Binding poses for the top six novel KOR ligand chemotypes
Hit compounds identified in primary round VLS and experimental evaluation are shown in 
stick representation with carbon atoms colored cyan. Receptor is shown by grey cartoon and 
sticks, and tightly bound water molecules directly involved in ligand binding as red spheres.
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Figure 4. Radioligand 6H-U69593 competition binding assays for the best hit analogs
Binding curves shown for the best sub-micromolar compounds resulted from initial scaffold 
optimization (see also Table 2 and Chart 3). Normalized results (mean ± SEM) from three 
independent assays (each in triplicate) were pooled and analyzed in GraphPad Prism.
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Figure 5. Docking poses of the top VLS hit derivatives
Compounds 64, 69, 81, 67, 72 and 87 are shown in sticks representaion. KOR is shown in 
cartoon representation with mutated residues as thin sticks, where white carbon atoms show 
side chains with no significant effect on ligand binding, green colored sticks show decrease 
in ligand binding upon mutation, while orange colored sticks show residues whose mutation 
led to increase in ligand binding. D138 side chain is shown for reference, though affinity 
data for D138A and D138N mutations were not obtained due to low affinity of 6H-U69593 
radioligand. Tightly bound water molecules directly involved in ligand binding are shown as 
red spheres.
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Figure 6. Functional characterization of the most potent ligands at KOR receptors
Selected compounds were tested in β-arrestin recruitment (a and b) and Gi-mediated 
inhibition of cAMP production (c). Values represented mean ± SEM from a minimum of 4 
measurements. Results were normalized and analyzed in Prism. (a) Relative antagonist and 
(b) agonist activity in recruiting β-arrestin at two ligand concentrations. Agonist activity was 
normalized to that of Sal A (100%) and antagonist activity was normalized to that of 5-
GNTI (100%). (c) Relative agonist activity in Gi-mediated inhibition of cAMP production. 
Results were normalized to that of Sal A (100%).
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Figure 7. Functional characterization of selected compounds
(a) KOR agonist activity of compounds 28 and 11 in β-arrestin recruitment and Gi-mediated 
inhibition of cAMP production, with Sal A as positive control. (b) Compound 64 
concentration-dependent inhibition of Sal A in β-arrestin recruitment assays with 5-GNTI as 
a positive control. (c) Compound 64 concentration-dependent inhibition of Sal A mediated 
Gi activation. Schild analysis resulted in pA2 of 6.78 ± 0.11 and Schild slope of 1.15 ± 0.06, 
and average KB = 0.017 μM. Results were normalized to fold of basal. (d) Comparison of 
compound 81 activity at both β-arrestin and Gi pathways. Values represented mean ± SEM 
from a minimum of 3 independent assays, each in triplicate or quadruplicate. Results were 
normalized, corrected with its nonspecific activity at control cells if necessary, and pooled 
for analysis in Prism.
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Chart 1. 
Examples of commonly used KOR small molecule agonists (U-50488, Salvinorin A), 
antagonist (JDTic), and G-protein biased ligands (RB-64 and 6′-GNTI).
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Chart 2. 
Chemical structures of VLS hit compounds in Table 1 with measured KOR Ki < 10 μM.
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Chart 3. 
Derivatives of the VLS hit compounds in Table 2 with sub-micromolar binding affinity to 
KOR. The six scaffolds in this chart and Chart S2 and are based on the initial VLS hits 28, 
11, 21, 43, 40, 6, respectively.
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